Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years

Table 2 mSASSS results for primary analysis set and for OASIS-Eligible patients

Cohort	Number	Mean change ± SD from baseline to year 2	Pvalue^a
Primary mSASSS analysis set
OASIS	169	0.9 ± 3.3	0.771
Adalimumab	307	0.8 ± 2.6
OASIS-Eligible patients
OASIS	77	0.9 ± 4.1	0.744
Adalimumab	307	0.8 ± 2.6

^aP value calculated using analysis of covariance model with therapy as a factor and baseline modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) as a covariate. OASIS, Outcome in Ankylosing Spondylitis International Study; SD, standard deviation.

ISSN: 1478-6362